ReviewFrontiers in oncology2023
Locoregional treatment of
Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Effect of locoregional surgery in primary tumors on overall survival in patients withFrontiers in oncology · 2025Pooled it
- ASO Author Reflections on "Variation in Surgical Management of Stage IV Breast Cancer: Local/Institutional and Regional Geographic Considerations."Annals of surgical oncology · 2026Article
- Advances in locoregional surgical treatment ofFrontiers in oncology · 2026Review
- A nomogram and risk stratification system for predicting survival in T1-2N0-1 breast cancer patients with liver metastasis in females: a population-based study.Biomedical engineering online · 2024Article
- Axillary lymph node removal inGland surgery · 2024Article
- Locoregional Radiotherapy in Patients with Advanced Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors Based on Real-World Data.Pharmaceuticals (Basel, Switzerland) · 2024Article
- The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting.Frontiers in oncology · 2024Article
- The Role of Primary Surgery inEuropean journal of breast health · 2023Review
- Primary site surgery of de novo stage IV HER2-positive breast cancer in the era of new drug treatments.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 6% of metastatic breast cancers arise
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.